Cargando…

Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients

BACKGROUND: KMT2 (lysine methyltransferase) family enzymes are epigenetic regulators that activate gene transcription. KMT2C is mainly involved in enhancer-associated H3K4me1, and is also one of the top mutated genes in cancer (6.6% in pan-cancer). Currently, the clinical significance of KMT2C mutat...

Descripción completa

Detalles Bibliográficos
Autores principales:	ZHU, SHA, XU, NANWEI, LIANG, JIAYU, ZHAO, FENGNIAN, WANG, ZILIN, NI, YUCHAO, DAI, JINDONG, ZHAO, JINGE, ZHANG, XINGMING, CHEN, JUNRU, SUN, GUANGXI, SHEN, PENGFEI, ZENG, HAO
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tech Science Press 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319590/ https://www.ncbi.nlm.nih.gov/pubmed/37415738 http://dx.doi.org/10.32604/or.2023.028321

Ejemplares similares

Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient’s CDK12 Mutation: A Case Report
por: Zhu, Sha, et al.
Publicado: (2022)

The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2022)

Exosomal TUBB3 mRNA expression of metastatic castration‐resistant prostate cancer patients: Association with patient outcome under abiraterone
por: Zhu, Sha, et al.
Publicado: (2021)

Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis
por: Chen, Junru, et al.
Publicado: (2022)

Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma
por: Zhao, Junjie, et al.
Publicado: (2022)

The value of transperineal apical prostate biopsy in predicting urethral/apical margin status after radical prostatectomy
por: Dai, Jindong, et al.
Publicado: (2019)

Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)
por: Zhu, Sha, et al.
Publicado: (2022)

The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis
por: Wang, Zhipeng, et al.
Publicado: (2020)

Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis
por: Chen, Junru, et al.
Publicado: (2020)

Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis
por: Chen, Junru, et al.
Publicado: (2020)

The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2021)

The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors
por: Zhang, Haoran, et al.
Publicado: (2020)

The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis
por: Chen, Junru, et al.
Publicado: (2018)

MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8
por: Shen, Pengfei, et al.
Publicado: (2020)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
por: Zhu, Xudong, et al.
Publicado: (2021)

Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients
por: Zeng, Yuhao, et al.
Publicado: (2023)

Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database
por: Chen, Junru, et al.
Publicado: (2019)

The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: a single-center retrospective study
por: Liu, Jiandong, et al.
Publicado: (2019)

The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma
por: Sun, Guangxi, et al.
Publicado: (2019)

The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis
por: Tao, Ronggui, et al.
Publicado: (2019)

Safety and efficacy associated with single-fraction high-dose-rate brachytherapy in localized prostate cancer: a systematic review and meta-analysis
por: Zeng, Hong, et al.
Publicado: (2023)

Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma
por: Zhang, Xingming, et al.
Publicado: (2018)

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

Primary renal mucinous adenocarcinoma masquerading as a giant renal cyst: a case report
por: Zeng, Hong, et al.
Publicado: (2023)

Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration‐resistant prostate cancer patients
por: Zhu, Sha, et al.
Publicado: (2021)

Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma
por: Sun, Guangxi, et al.
Publicado: (2021)

Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors
por: Dhar, Shilpa S., et al.
Publicado: (2021)

Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer
por: Rodriguez-Casanova, Aitor, et al.
Publicado: (2021)

Cancer metabolites: promising biomarkers for cancer liquid biopsy
por: Wang, Wenxiang, et al.
Publicado: (2023)

The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy
por: Zhao, Jinge, et al.
Publicado: (2017)

Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma
por: López, Virginia, et al.
Publicado: (2021)

Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma
por: Liang, Jiayu, et al.
Publicado: (2023)

Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy
por: Gai, Wanxia, et al.
Publicado: (2019)

Epigenetic Biomarkers of Renal Cell Carcinoma for Liquid Biopsy Tests
por: Kubiliute, Raimonda, et al.
Publicado: (2021)

Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies
por: Palanca-Ballester, Cora, et al.
Publicado: (2021)

The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis
por: Zhang, Xingming, et al.
Publicado: (2017)

Regulation of IL-20 Expression by Estradiol through KMT2B-Mediated Epigenetic Modification
por: Su, Chia-Hsin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uj1ob97llf441aogu9uaf57sj4